This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Should intravitreal steroids be used in the initial treatment of post-op endophthalmitis?

Should intravitreal steroids be used in the initial treatment of post-op endophthalmitis?
Reviewed by Eulee Seow

1 October 2018 | Eulee Seow | EYE - Cataract, EYE - Refractive | adjuvant intravitreal dexamethasone, cataract surgery, postoperative bacterial endophthalmitis, randomized controlled trial

Endophthalmitis following cataract surgery is one of the most feared complications, and can have significant impact on the visual outcomes of patients. The role of steroids in the management of endopthalmitis is controversial. The aim of this paper was to determine whether intravitreal dexamethasone as an adjuvant to intravitreal antibiotics is beneficial in the treatment of suspected bacterial endophthalmitis after cataract surgery. This is a randomised, placebo‐controlled superiority trial in three tertiary referral centres in the Netherlands. Patients with suspected bacterial endophthalmitis within six weeks after cataract surgery were eligible. A diagnostic vitreous biopsy was taken for culture, and patients received intravitreal injections of 400μg dexamethasone (without preservatives) or placebo, in addition to 0.2mg vancomycin and 0.05mg gentamicin. The vancomycin and dexamethasone or placebo injections were repeated once at day three or four. Primary outcome measure was best‐corrected visual acuity (BCVA) at one year. Over 10 years a total of 167 patients (81 dexamethasone, 86 placebo) were available for the intention‐to‐treat analysis. Biopsies of 114 patients (68%) were culture‐positive. Final BCVA did not differ between the dexamethasone and the placebo group (logMAR 0.31±0.58 versus 0.27±0.50; p=0.90), nor did the number of patients with final vision of no light perception (LP, 7 versus 13). This study concluded that intravitreal dexamethasone without preservatives as an adjuvant to intravitreal antibiotics does not improve visual acuity (VA) in patients treated for suspected bacterial endophthalmitis after cataract surgery. 

A prospective multi-centre randomized placebo‐controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics.
Manning S, Ugahary LC, Lindstedt EW, et al.
ACTA OPHTHALMOLOGICA
2018;96:348-55.
Share This
CONTRIBUTOR
Eulee Seow

University Hospital of Wales, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency